NHS Ayrshire & Arran Formulary Bulletin - NHS Ayrshire and Arran.

Medicines launched, not yet reviewed and not for prescribing
The following are medicines that have been launched or have had an extension to their licensed indications
but have not as yet been considered by the ADTC. Since they have yet to be considered by the SMC, they
are therefore NOT recommended for prescribing within NHS Ayrshire & Arran until a decision is
communicated from the ADTC. They are however available on an exceptional case application basis.
Requests should be sent to the Medical Director for consideration.
Adalimumab (Humira ® ) - polyarticular juvenile Grass Pollen Extract (Grazax ® ) tabs – children
idiopathic arthritis in children from 4 years-old
Alemtuzumab (MabCampath ® ) inf – first line CLL Glatiramer (Copaxone ® ) injection – treatment first episode
and those at high risk of developing MS
Azithromycin (Azyter ® ) eyedrops – conjunctivitis Ipilimumab (Yervoy ® ) injection – advanced melanoma
Aztreonam (Cayston ® ) nebs – cystic fibrosis L-carnitine (Carnitor ® ) tablets carnitine deficiency
Boceprevir capsules (Victrelis ® ) – hepatitis C Midazolam (buccal) – status epilepticus
Bortezomib (Velcade ® ) – untreated multiple Moxifloxacin (Avelox ® ) –complicated skin infections
myeloma with melphalan & prednisolone
Botulinum toxin type A (Xeomin ® ) – post stroke Olmesartan/ amlodipine and hydrochlorothiazide
spasticity of the upper limb.
(SEVIKAR HCT ® ) - hypertension
Bromfenac (Yellox ® ) eye drops – cataract surgery Phenylephrine + tropicamide (Mydriasert ® ) Opthalmic
insert – diagnostic eye surgery
C1-Esterase inhibitor (Berinert ® ) – Hereditary Prednisone (Lodotra ® ) m/r tablets – moderate to severe
angioedema type I and II (acute episode)
active rheumatoid arthritis
Cabazitaxel (Jevtana ® ) – prostate cancer
Ramipril (Tritace ® ) – treatment of incipient glomerular
diabetic neuropathy
Carmellose/ Glycerine (Optive ® ) eyedrops – dry Ranibizumab (Lucentis ® ) intravitreal injection – retinal vein
eyes
occlusion
Catumaxomab (Removab ® ) injection - malignant Recombinant Antithrombin (Atryn ® ) – prophylaxis of
ascites
Dasatinib (Sprycel ® ) - newly diagnosed Philadelphia
chromosome positive chronic myelogenous
leukaemia in the chronic phase
Doripenem (Doribax) inj –complicated UTIs
Doxycycline (Efracea ® ) capsules – treatment of
rosacea
Eribulin (Halaven ® ) injection – metastatic breast
cancer
Ertapenem (Invanz ® ) inj – community acquired
pneumonia & acute gynaecological infections
Exenatide once weekly injection (Bydureon ® ) – type
2 diabetes mellitus
Fingolimod (Gilenya ® ) capsules – multiple sclerosis
venous thromboembolism
Salicylic acid and fluorouracil (Actikerall ® ) topical solution –
actinic keratosis
Saxagliptin (Onglyza ® ) tabs – type 2 diabetes in
combination with sulphonylureas or thiazolidinedione
Sitagliptin (Januvia ® ) tabs – type 2 diabetes mellitus in
combination with thiazolidinediones
Somatropin (Humatrope ® ) inj – growth disturbance in short
children. Growth failure associated with SHOX deficiency
Temsirolimus (Torisel ® ) infusion – advanced renal cell
cancer
Travoprost (Travatan ® ) eye drops - benzalkonium chloride
free multidose formulation
Urofollitropin (Fostimon ® ) injection – infertility
NHS Ayrshire & Arran Formulary Bulletin, Medicines Utilisation Unit August & September 2011 Page 8 of 8